- Home
- ELVN vs EOS Comparison
ELVN vs EOS Comparison
Compare ELVN & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- EOS
- Stock Information
- Founded
- ELVN 2016
- EOS 2005
- Country
- ELVN United States
- EOS United States
- Employees
- ELVN N/A
- EOS N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- EOS Trusts Except Educational Religious and Charitable
- Sector
- ELVN Health Care
- EOS Finance
- Exchange
- ELVN Nasdaq
- EOS Nasdaq
- Market Cap
- ELVN 1.1B
- EOS 1.2B
- IPO Year
- ELVN 2020
- EOS N/A
- Fundamental
- Price
- ELVN $22.47
- EOS $23.81
- Analyst Decision
- ELVN Strong Buy
- EOS
- Analyst Count
- ELVN 5
- EOS 0
- Target Price
- ELVN $37.80
- EOS N/A
- AVG Volume (30 Days)
- ELVN 204.7K
- EOS 84.1K
- Earning Date
- ELVN 11-13-2024
- EOS 01-01-0001
- Dividend Yield
- ELVN N/A
- EOS 6.80%
- EPS Growth
- ELVN N/A
- EOS N/A
- EPS
- ELVN N/A
- EOS N/A
- Revenue
- ELVN N/A
- EOS N/A
- Revenue This Year
- ELVN N/A
- EOS N/A
- Revenue Next Year
- ELVN N/A
- EOS N/A
- P/E Ratio
- ELVN N/A
- EOS N/A
- Revenue Growth
- ELVN N/A
- EOS N/A
- 52 Week Low
- ELVN $10.90
- EOS $15.62
- 52 Week High
- ELVN $30.03
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- ELVN 39.53
- EOS 56.42
- Support Level
- ELVN $21.84
- EOS $23.47
- Resistance Level
- ELVN $24.42
- EOS $24.30
- Average True Range (ATR)
- ELVN 1.59
- EOS 0.31
- MACD
- ELVN -0.05
- EOS -0.07
- Stochastic Oscillator
- ELVN 18.27
- EOS 44.94
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. It invests in a portfolio of large and mid-cap securities in the sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.